annual meeting program - American Society of Clinical Oncology

Saturday, June 5, 2010
Brd. 20 A phase I study of the mTOR inhibitor sirolimus in combination with
nanoparticle albumin-bound paclitaxel (nab-P). (Abstract #2534^)
M. M. Abu-Khalaf, S. N. Gettinger, V. N. Trieu, H. A. Deshpande, M. DiGiovanna,
M. Azodi, N. Desai, W. K. Kelly, P. E. Schwartz, L. Harris
Brd. 21 A phase I study of gemcitabine, capecitabine, and vandetanib in patients with
advanced solid tumors with an expanded cohort in biliary and pancreatic
malignancies. (Abstract #2535)
S. Nallapareddy, S. G. Eckhardt, C. L. O’Bryant, S. Eppers, S. Diab, M. A. Kane,
C. D. Weekes, J. L. Spratlin, W. A. Messersmith, S. Leong
Brd. 22 A phase I study of aflibercept, pemetrexed (P), and cisplatin (C) in patients
with advanced solid tumors. (Abstract #2536)
C. A. Townsley, L. L. Siu, M. San Pedro-Salcedo, L. Liu, H. A. Wakelee
Brd. 23 Targeted cancer therapies: FDA approval overview. (Abstract #2537)
P. Cortazar, P. Keegan, R. L. Justice, J. R. Johnson, R. Pazdur
Brd. 24 Phase IB dose escalation study of bortezomib and sunitinib in patients with
refractory solid tumors. (Abstract #2538)
J. S. Kauh, R. D. Harvey, D. H. Lawson, T. K. Owonikoko, M. Tighiouart,
S. S. Ramalingam, D. M. Shin, C. M. Lewis, B. F. El-Rayes, F. R. Khuri
123
SATURDAY